(Q39589735)

13 September 2017

title

Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing (English)

1 reference

13 September 2017

1 reference

6

Bjarne Bogen

1 reference

13 September 2017

4

Tobias Gedde-Dahl

1 reference

13 September 2017

2

Pier Adelchi Ruffini

1 reference

13 September 2017

Marianne Frøyland

1

1 reference

13 September 2017

Keith Michael Thompson

series ordinal

3

1 reference

13 September 2017

Agnete Brunsvik Fredriksen

series ordinal

5

1 reference

13 September 2017

publication date

30 March 2011

1 reference

European Journal of Haematology

13 September 2017

published in

1 reference

13 September 2017

volume

86

1 reference

13 September 2017

issue

5

1 reference

13 September 2017

page(s)

385-395

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

13 September 2017

1 reference

Individualizing treatment of patients with myeloma in the era of novel agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Myeloma proteins as tumor-specific transplantation antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Delivery of antigen to CD40 induces protective immune responses against tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

The role of complete response in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Importance of achieving a complete response in multiple myeloma, and the impact of novel agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

International uniform response criteria for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Recombinant antibodies as carrier proteins for sub-unit vaccines: influence of mode of fusion on protein production and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Growth inhibition of myeloma cells by anti-idiotype antibodies in the absence of membrane-bound immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Multiple myeloma cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Naive idiotype-specific CD4+ T cells and immunosurveillance of B-cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Primary antitumor immune response mediated by CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Roles of idiotype-specific t cells in myeloma cell growth and survival: Th1 and CTL cells are tumoricidal while Th2 cells promote tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Idiotypes and Anti-idiotypes as Probes in Analysis of Immunoregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Production of auto-anti-idiotypic antibody during the normal immune response to TNP-ficoll. III. Absence in nu/nu mice: evidence for T-cell dependence of the anti-idiotypic-antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Clonal deletion of thymocytes as a tumor escape mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Review: to what extent are T cells tolerant to immunoglobulin variable regions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Human chemokine MIP1α increases efficiency of targeted DNA fusion vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Electroporation for DNA immunization: clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0609.2011.01590.X

10.1111/J.1600-0609.2011.01590.X

21 January 2018

Identifiers

DOI

1 reference

13 September 2017

1 reference